Redmile Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Redmile Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-75,000	Closed	-$215K	–	66
2019 Q3	$215K	Buy	+75,000	New	+$233K	0.01%	70

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Redmile Group's BCRX Position: Q4 2019 in Review

Redmile Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2019, closing a stake of 75,000 shares — an estimated $215K sold.

Redmile Group first reported a position in BCRX in Q3 2019 and held it in 1 quarter. The position peaked at $215K in Q3 2019. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

Redmile Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Redmile Group sold 75,000 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $215K.
Redmile Group first reported a position in BioCryst Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Redmile Group's BioCryst Pharmaceuticals position peaked at $215K in Q3 2019.
136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.